Statement: Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment).
Primary_evidence: Outcome Measurement:    Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment   [Not Specified]   Time frame: 6 months Results 1:    Arm/Group Title: AC/PTL   Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.   Overall Number of Participants Analyzed: 109   Measure Type: Number   Unit of Measure: participants  0